Iván A. González, Hsiang‐Chih Lu, Zahra Alipour, Sakil S. Kulkarni, Janis M. Stoll, Kim H.H. Liss, Louis P. Dehner, Mai He – 30 November 2020 – Centrilobular injury (CLI) is defined as the presence of perivenular mononuclear inflammation, hepatocyte dropout, and extravasated erythrocytes. In pediatric liver allografts, CLI has been associated with advanced fibrosis and chronic rejection (CR). We sought to better characterize the clinicopathologic features of CLI in the setting of T cell–mediated rejection (TCMR) and its association with complement component 4d (C4d) deposition.

Joy Varghese, Selvakumar Malleeswaran, Rajanikanth V. Patcha, Ellango Appusamy, Perumal Karnan, Dharmesh Kapoor, Kota Venugopal, Chandhan Kumar Kedarisetty, Balbir Singh, Prashantha S. Rao, Raghavendra Babu Yalakanti, Ravi Mohanka, Anurag Shrimal, Vinayak Nikam, Karan Kumar, Sunil D. Shenvi, Bhaskaran Pillai Venugopal, Nigel D. Heaton – 30 November 2020

Prashant Bhangui, Sanjiv Saigal, Dheeraj Gautam, Tarun Piplani, Narendra Choudhary, Rohan Chaudhary, Sanjay Yadav, S. Thiagarajan, Amit Rastogi, Neeraj Saraf, Samiran Nundy, A.S. Soin – 30 November 2020 – Conventional selection criteria for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) are based on tumour size/number only, and do not consider vital surrogates of tumor biology such as alpha‐fetoprotein (AFP) and tumor [18F]fluorodeoxyglucose positron emission tomography ([18F]FDG PET) avidity.

May S. Freag, Bumseok Namgung, Maria E. Reyna Fernandez, Ermanno Gherardi, Shiladitya Sengupta, Hae Lin Jang – 29 November 2020 – Nonalcoholic steatohepatitis (NASH), an advanced stage of nonalcoholic fatty liver disease (NAFLD), is a rapidly growing and global health problem compounded by the current absence of specific treatments. A major limiting factor in the development of new NASH therapies is the absence of models that capture the unique cellular structure of the liver microenvironment and recapitulate the complexities of NAFLD progression to NASH.

Tracey G. Simon, Andrew T. Chan, Curtis Huttenhower – 29 November 2020

Philip R. Spradling, Yuna Zhong, Anne C. Moorman, Loralee B. Rupp, Mei Lu, Stuart C. Gordon, Eyasu H. Teshale, Mark A. Schmidt, Yihe G. Daida, Joseph A. Boscarino, for the Chronic Hepatitis Cohort Study (CHeCS) Investigators – 29 November 2020 – There are limited data examining the relationship between psychosocial factors and receipt of direct‐acting antiviral (DAA) treatment among patients with hepatitis C in large health care organizations in the United States. We therefore sought to determine whether such factors were associated with DAA initiation.

Morteza Hafezi, Meiyin Lin, Adeline Chia, Alicia Chua, Zi Zong Ho, Royce Fam, Damien Tan, Joey Aw, Andrea Pavesi, Thinesh Lee Krishnamoorthy, Wan Cheng Chow, Wenjie Chen, Qi Zhang, Lu‐En Wai, Sarene Koh, Anthony T. Tan, Antonio Bertoletti – 29 November 2020

Hye‐Mee Kwon, Young‐Jin Moon, Kyoung‐Sun Kim, Won‐Jung Shin, In‐Young Huh, In‐Gu Jun, Jun‐Gol Song, Gyu‐Sam Hwang – 28 November 2020

Diana Apetauerova, Peter Hildebrand, Stephanie Scala, Janet W. Zani, LeeAnne Lipert, Erin Clark, Tanya Fennell, Fredric D. Gordon – 26 November 2020 – Acquired hepatocerebral degeneration refers to a neurological syndrome consisting of various movement disorders and cognitive impairment in advanced liver cirrhosis or portosystemic shunt. Neurological signs and symptoms may be attributed to the accumulation of toxic substances in the brain. The most common neurological presentation of this is parkinsonism.

Gabriela Hernandez‐Meza, Johann Felden, Edgar E. Gonzalez‐Kozlova, Teresa Garcia‐Lezana, Judit Peix, Anna Portela, Amanda J. Craig, Sergi Sayols, Myron Schwartz, Bojan Losic, Vincenzo Mazzaferro, Manel Esteller, Josep M. Llovet, Augusto Villanueva – 25 November 2020